Pluri (PLUR) Income from Non-Controlling Interests (2022 - 2025)
Pluri (PLUR) reported Income from Non-Controlling Interests of -$329000.0 for Q4 2025, down 113.64% year-over-year from $2.4 million in Q4 2024, and down 16.67% quarter-over-quarter from -$282000.0 in Q3 2025.
Pluri (PLUR) Income from Non-Controlling Interests (2022 - 2025) Analysis & Trends
Pluri (PLUR) has 4 years of Income from Non-Controlling Interests data on file, last reported at -$329000.0 in Q4 2025.
- Income from Non-Controlling Interests for Q4 2025 came in at -$329000.0, down 113.64% year-over-year; the trailing twelve-month figure through Dec 2025 was -$970000.0 (down 80.3% YoY), and the FY2025 annual result was -$667000.0, down 46.27% from the prior year.
- Income from Non-Controlling Interests slipped to -$329000.0 in Q4 2025 per PLUR's latest filing, from -$282000.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at -$53000.0 in Q1 2022 and troughed at -$329000.0 in Q4 2025.
- A 4-year average of -$152000.0 and a median of -$142000.0 in 2022 frame the typical range for Income from Non-Controlling Interests.
- On a YoY basis, Income from Non-Controlling Interests climbed as much as 35.04% in 2023 and fell as far as 152.83% in 2023.
- A 4-year view of Income from Non-Controlling Interests shows it stood at -$137000.0 in 2022, then surged by 35.04% to -$89000.0 in 2023, then tumbled by 73.03% to -$154000.0 in 2024, then tumbled by 113.64% to -$329000.0 in 2025.
- Business Quant data shows PLUR's Income from Non-Controlling Interests at -$329000.0 in Q4 2025, -$282000.0 in Q3 2025, and -$171000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Pluri | 21.85 Mn | 22.34 Mn | 86,000.00 | -329,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -329,000.00 |
| Sep 30, 2025 | -282,000.00 |
| Jun 30, 2025 | -171,000.00 |
| Mar 31, 2025 | -188,000.00 |
| Dec 31, 2024 | -154,000.00 |
| Sep 30, 2024 | -154,000.00 |
| Jun 30, 2024 | -133,000.00 |
| Mar 31, 2024 | -97,000.00 |
| Dec 31, 2023 | -89,000.00 |
| Sep 30, 2023 | -137,000.00 |
| Jun 30, 2023 | -147,000.00 |
| Mar 31, 2023 | -134,000.00 |
| Dec 31, 2022 | -137,000.00 |
| Sep 30, 2022 | -148,000.00 |
| Jun 30, 2022 | -79,000.00 |
| Mar 31, 2022 | -53,000.00 |